Orthocell Ltd - Asset Resilience Ratio

Latest as of June 2025: 81.22%

Orthocell Ltd (OCC) has an Asset Resilience Ratio of 81.22% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Orthocell Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

AU$28.62 Million
≈ $20.25 Million USD Cash + Short-term Investments

Total Assets

AU$35.24 Million
≈ $24.93 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Orthocell Ltd's Asset Resilience Ratio has changed over time. See Orthocell Ltd net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Orthocell Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OCC company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$28.62 Million 81.22%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$28.62 Million 81.22%

Asset Resilience Insights

  • Very High Liquidity: Orthocell Ltd maintains exceptional liquid asset reserves at 81.22% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Orthocell Ltd Industry Peers by Asset Resilience Ratio

Compare Orthocell Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 1.39%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shanghai Shen Lian Biomedical Corp
SHG:688098
Biotechnology 3.87%

Annual Asset Resilience Ratio for Orthocell Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Orthocell Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 75.20% AU$26.50 Million
≈ $18.75 Million
AU$35.24 Million
≈ $24.93 Million
-2.25pp
2024-06-30 77.45% AU$20.61 Million
≈ $14.59 Million
AU$26.62 Million
≈ $18.83 Million
-6.38pp
2023-06-30 83.83% AU$24.82 Million
≈ $17.56 Million
AU$29.61 Million
≈ $20.95 Million
+54.75pp
2022-06-30 29.08% AU$11.02 Million
≈ $7.80 Million
AU$37.90 Million
≈ $26.81 Million
-55.39pp
2021-06-30 84.47% AU$16.33 Million
≈ $11.55 Million
AU$19.33 Million
≈ $13.68 Million
-3.75pp
2020-06-30 88.22% AU$20.44 Million
≈ $14.46 Million
AU$23.17 Million
≈ $16.39 Million
+5.59pp
2019-06-30 82.63% AU$11.24 Million
≈ $7.95 Million
AU$13.60 Million
≈ $9.62 Million
+26.99pp
2018-06-30 55.65% AU$2.91 Million
≈ $2.06 Million
AU$5.23 Million
≈ $3.70 Million
-14.84pp
2017-06-30 70.49% AU$5.05 Million
≈ $3.57 Million
AU$7.16 Million
≈ $5.07 Million
--
pp = percentage points

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$164.13 Million
AU$231.97 Million AUD
Market Cap Rank
#17278 Global
#507 in Australia
Share Price
AU$0.86
Change (1 day)
-2.29%
52-Week Range
AU$0.72 - AU$1.53
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more